Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...
Hosted on MSN10hOpinion
New Strong Buy Stocks for December 2ndList today: Embecta Corp. EMBC: This medical device company has seen the Zacks Consensus Estimate for its current year ...
Dynamic Technology Lab Private Ltd lessened its stake in Embecta Corp. (NASDAQ:EMBC – Free Report) by 6.4% during the 3rd ...
Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.
Zacks.com on MSN14hOpinion
Best Value Stocks to Buy for December 2ndHere are three stocks with buy rank and strong value characteristics for investors to consider today, December 2: Embecta ...
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...
Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...
Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 ...
BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...
Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback